Scientific article
English

Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats

Published in

Transplantation, vol. 87, no. 1, p. 59-65

Publication date

2009

Abstract

BACKGROUND: AEB-071 (AEB) is a specific inhibitor of protein kinase C, which prevents T-lymphocyte activation. The present study investigated the effect of AEB on rat islet allotransplantation alone or in combination with CTLA4-Ig, mycophenolate mofetil, or cyclosporine A (CsA). METHODS: A rodent allogeneic islet transplant model (Lewis to Wistar Furth) was used to investigate the efficacy of AEB as an immunosuppressive agent. Furthermore, the Lewis rat was used to screen for any AEB associated toxicities on glucose homeostasis in vivo. RESULTS: AEB alone (30 mg/kg per os [p.o.] two times per day [bid]) delayed rejection to a median survival time of 22 days (vs. 7 days in control vehicle-treated animals, P<0.05). When combined with CsA (5 mg/kg p.o. bid), AEB prolonged survival from 12 (CsA alone) to over 100 days in 80% of animals (P<0.05). No delay in allograft rejection (above that resulting from AEB alone) was observed when AEB was combined with a sub-therapeutic dose of CTLA4-Ig or mycophenolate mofetil, nor low dose of CsA. The frequency of allospecific interferon-gamma-secreting splenocytes, assessed ex vivo by enzyme-linked immunosorbent spot (ELISPOT) assay, was lower in AEB-treated recipients compared with controls (P<0.05). AEB treatment did not alter the intraperitoneal glucose tolerance, the glucose-dependent insulin release, or the insulin content of the native pancreas. CONCLUSIONS: These data suggest that AEB is an appropriate immunosuppressive agent for islet transplantation, as it can prolong islet graft survival alone or in combination with CsA, without toxicity on glucose metabolism.

Keywords

  • Animals
  • Autoimmunity/immunology
  • CD4-Positive T-Lymphocytes/drug effects/immunology
  • CD8-Positive T-Lymphocytes/drug effects/immunology
  • Cyclosporine/pharmacology
  • Drug Synergism
  • Female
  • Graft Rejection/immunology/metabolism/*prevention & control
  • Immunosuppressive Agents/*pharmacology
  • Insulin/metabolism
  • Islets of Langerhans/physiology
  • *Islets of Langerhans Transplantation
  • Male
  • Protein Kinase C/*antagonists & inhibitors/metabolism
  • Protein Kinase Inhibitors/*pharmacology
  • Rats
  • Time Factors
  • Transplantation, Homologous

Citation (ISO format)

MERANI, Shaheed et al. Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats. In: Transplantation, 2009, vol. 87, n° 1, p. 59–65. doi: 10.1097/TP.0b013e31819198b4

Main files (1)

Article

Identifiers

Journal ISSN

0041-1337
565views
0downloads

Technical informations

Creation

23/04/2012 13:24:21

First validation

23/04/2012 13:24:21

Update

14/10/2025 00:14:26

Status update

14/03/2023 17:26:08

Last indexation

04/02/2026 14:46:16
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated